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A B S T R A C T
Schizophrenia is believed to be a neurodevelopmental disease with high heritability. Differential diagnosis is
often challenging, especially in early phases, namely with other psychotic disorders or even mood disorders.
such as bipolar disorder with psychotic symptoms. Key pathophysiological changes separating these two clas-
sical psychoses remain poorly understood, and current evidence favors a more dimensional than categorical
differentiation between schizophrenia and bipolar disorder. While established biomarkers like cortical thickness
and grey matter volume are heavily influenced by post-onset changes and thus provide limited possibility of
accessing early pathologies, gyrification is assumed to be more specifically determined by genetic and early
developmental factors. The aim of our study was to compare both classical and novel morphometric features in
these two archetypal psychiatric disorders. We included 20 schizophrenia patients, 20 bipolar disorder patients
and 20 age- and gender-matched healthy controls. Data analyses were performed with CAT12/SPM12 applying
general linear models for four morphometric measures: gyrification and cortical thickness (surface-based mor-
phometry), and whole-brain grey matter/grey matter volume (voxel-based morphometry - VBM). Group effects
were tested using age and gender as covariates (and total intracranial volume for VBM). Voxel-based morpho-
metry analysis revealed a schizophrenia vs. control group effect on regional grey matter volume (p < 0.05,
familywise error correction) in the right globus pallidus. There was no group effect on white matter volume
when correcting for multiple comparisons neither on cortical thickness. Gyrification changes in clinical samples
were found in the left supramarginal gyrus (BA40) – increased and reduced gyrification, respectively, in BPD and
SCZ patients - and in the right inferior frontal gyrus (BA47), with a reduction in gyrification of the SCZ group
when compared with controls. The joint analysis of different morphometric features, namely measures such as
gyrification, provides a promising strategy for the elucidation of distinct phenotypes in psychiatric disorders.
Different morphological change patterns, highlighting specific disease trajectories, could potentially generate
neuroimaging-derived biomarkers, helping to discriminate schizophrenia from bipolar disorder in early phases,
such as first-episode psychosis patients.
1. Introduction
The classical dichotomy between schizophrenia (SCZ) and bipolar
disorder (BPD) proposed by Kraepelin has dominated western psy-
chiatry for over a century, and only recently has a distinction that could
be more dimensional than categorical emerged (Craddock et al., 2009).
Several studies have documented a high genetic overlap between SCZ
and BPD (Cross-Disorder Group of the Psychiatric Genomics, 2013;
Hammerschlag et al., 2019). Clinically, early phases of SCZ and BPD
can be hard to differentiate due to common presentations, especially
when psychotic symptoms are prominent in BPD. In the AESOP-10
study, around 30% of patients who had a first-episode psychosis were
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later diagnosed with an affective psychosis (BPD or unipolar depres-
sion) over a 10-year follow-up (Morgan et al., 2014). Identification of
diagnosis-specific biomarkers that can help to differentiate SCZ and
BPD has been the subject of intensive investigation, not least because
the treatment options are substantially different and might impact
morbidity and mortality.
Structural brain changes are good candidates for exploration as
biological markers in both conditions (Lewis and Levitt, 2002;
Rapoport et al., 2012). A seminal computerized tomography (CT) study
documented increased ventricular volume in patients with SCZ com-
pared to age-matched controls (Johnstone et al., 1976), and ventricular
enlargement and deep regional grey matter volumes measured using
voxel-based morphometry are to date the most consistent and re-
plicated neuroimaging findings in SCZ (Brugger and Howes, 2017;
Glahn et al., 2008).
A comparative meta-analysis of voxel-based morphometry studies
has shown extensive grey matter (GM) loss in frontotemporal, cingulate
and insular cortices, and increased GM in basal ganglia in SCZ, while in
BPD grey matter reductions were present in the anterior cingulate
cortex and the insula (Ellison-Wright and Bullmore, 2010). Recently, a
direct comparison of SCZ vs. BPD suggested that more extensive pre-
frontal, thalamic, and hippocampal deficits might set apart schizo-
phrenia, although authors could not exclude effects of clinical hetero-
geneity, especially in BPD patients, namely comorbid psychotic
symptoms (Nenadic et al., 2015b). Gender differences in GM volumes
are a known source of heterogeneity in comparisons between SCZ and
BPD; when gender is controlled for, GM abnormalities are mostly re-
stricted to fronto-insular cortex in BPD and dorsolateral prefrontal
cortex in SCZ, while GM reduction of the anterior cingulate cortex is
seen in both populations (Bora et al., 2012). Disease stage/chronicity of
disease (Chan et al., 2011; Shah et al., 2016) and antipsychotic treat-
ment (Torres et al., 2013) are additional sources of variability in VBM
analyses.
Surface-based morphometry techniques enable the analysis of ad-
ditional brain features including surface area, curvature, cortical
thickness (Fischl and Dale, 2000) and cortical gyrification (Schaer et al.,
2008). Cortical thickness has been shown to be reduced in schizo-
phrenia in prefrontal and temporal cortical areas (Besteher et al., 2016;
Goldman et al., 2009; Kubota et al., 2011; Nesvåg et al., 2008), but the
effects are also modulated by illness duration and antipsychotic treat-
ment (van Haren et al., 2011). Cortical structural changes in BPD pa-
tients are less prominent except in patients with comorbid psychosis
(Godwin et al., 2018; Hibar et al., 2018; Rimol et al., 2012).
Cortical gyrification of the brain represents the characteristic
folding of the cerebral cortex. It has been hypothesized that alternative
neuroimaging biomarkers might be more disease-specific and could
help disentangle shared findings in both SCZ and BPD, and potentially
overperform classical markers such as cortical thickness and GM vo-
lume, which may be more influenced by post-onset pathological pro-
cesses (Nenadic et al., 2015a). Cortical gyrification has been proposed
as a novel schizophrenia endophenotype candidate, since it targets
morphometric properties which are not captured by VBM or cortical
thickness analyses, and is assumed to be more specifically determined
by genetic and developmental factors (Nenadic et al., 2015a;
Zilles et al., 2013, 1988). Accordingly, we have recently shown that a
monogenetically determined neurodevelopmental disorder, Neurofi-
bromatosis Type 1 is characterized by abnormal gyrification which is
consistent with patterns of cognitive dysfunction observed in this con-
dition (Violante et al., 2013). This feature has also been explored in
schizophrenia, modelled as a late neurodevelopmental disorder with
high heritability (Matsuda and Ohi, 2018; Spalthoff et al., 2018). While
abnormal cortical gyrification has been reported in patients with SCZ,
patient relatives and at-risk individuals, conflicting findings of hyper-
and hypo-gyrification have been reported which may be explained by
different estimation methods and other factors such as age, gender and
illness stage and severity (Matsuda and Ohi, 2018). Cortical gyrification
can be quantified as a gyrification index (GI), which in SCZ and BPD has
been shown to decrease at a faster pace than in healthy controls during
aging, especially after the age of 40 (Bo Cao et al., 2017). Evidence
regarding gyrification changes in BPD is more scarce, but studies have
shown reduced prefrontal gyrification and a significant disease-stage
effect on the GI of patients with BPD (B. Cao et al., 2017;
McIntosh et al., 2009).
An important caveat of case-control studies, which dominate the
field of neuroimaging in psychiatry, is that patients are enrolled based
on a specific clinical diagnosis and are compared with healthy in-
dividuals, but typically not to another clinical group (Etkin, 2019).
Taking into account other previous limitations in studying brain
structural differences between SCZ and BPD, our main purpose was to
directly compare carefully defined matched-groups of bipolar disorder
(BPD) vs. schizophrenia (SCZ) patients and healthy controls using both
conventional (GM volume and cortical thickness) and novel (gyrifica-
tion index) morphometric features of these archetypal psychiatric dis-
orders. We hypothesize that analyzing well-matched disease popula-
tions will allow the isolation of disease-specific morphometric markers
which may inform and guide future research.
2. Methods
2.1. Participants
We included outpatients with schizophrenia (SCZ) and bipolar dis-
order (BPD) from a major university hospital, besides healthy controls
(CNT), matched for age, gender and education. Inclusion criteria for
clinical groups were: (1) ICD-10 criteria for SCZ or BPD using a semi-
structured interview (Martins et al., 2019); (2) age between 18–54; (3)
capacity to consent; (4) right-handedness through evaluation with the
Edinburgh Handedness Inventory (Espírito-Santo et al., 2017); (5)
clinical stability in the last 12 weeks prior to enrollment. General ex-
clusion criteria were: (1) medical or neurological comorbidity (e.g.
epilepsy, head trauma, neurodevelopmental disorders); (2) substance
abuse/dependence; (3) contra-indications to magnetic resonance ima-
ging. Patients’ clinical assessment included instruments such as the
Brief Psychiatric Rating Scale – BPRS (Lukoff et al., 1986) for general
psychopathology, and the Personal and Social Performance Scale – PSP
(Brissos et al., 2012) addressing functioning; insight was measured
through the Insight and Treatment Attitudes Questionnaire, ITAQ
(McEvoy et al., 1989). The Schizo-Bipolar Scale (Keshavan et al., 2011),
developed to capture the dimensional interaction between psychosis
and affective symptoms, was also administered. Current antipsychotic
exposure in patient groups (SCZ and BPD) was calculated through
chlorpromazine equivalents – CPZE (Atkins et al., 1997). Control in-
dividuals were recruited from the institution's workers and their re-
latives, and a brief interview excluded a personal or family history of
mental disorders, namely SCZ or BPD, in addition to general exclusion
criteria. All participants provided written informed consent to a study
approved by the local Ethics Committee of the Faculty of Medicine of
the University of Coimbra (ref. CE-010/2014) and in accordance with
the Declaration of Helsinki.
2.2. Magnetic resonance imaging (MRI) acquisition
Data were collected with a Siemens Magnetom TIM Trio 3 Tesla
scanner (Siemens, Munich, Germany) with a phased array 12-channel
birdcage head coil. We acquired a 3D anatomical T1-weighted MPRAGE
(magnetization-prepared rapid gradient echo) magnetic resonance
imaging pulse sequence (TR 2530 ms; TE 3.42 ms; TI = 1100 ms; flip
angle 7°; 176 single-shot interleaved slices with no gap with isotropic
voxel size 1 × 1 × 1 mm; FOV 256 mm) of all 60 participants.
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2.3. Pre-processing
All images were processed and analyzed using the CAT12 toolbox
(C. Gaser, Structural Brain Mapping Group, Jena University Hospital,
Jena, Germany; http://dbm.neuro.uni-jena.de/cat/) implemented in
SPM12 (Wellcome Trust center for Neuroimaging, London, UK; http://
www.fil.ion.ucl.ac. uk/spm/software/spm12/). CAT12 served as the
platform for all the analyses, as it offers processing pipelines for both
voxel-based morphometry as well as surface-based morphometry (in-
cluding cortical thickness and gyrification), allowing us to perform all
analyses with this software package. For processing- and analysis-steps,
pre-set parameters in accordance with standard protocol (http://www.
neuro.uni-jena.de/cat12/CAT12-Manual.pdf) were used, applying de-
fault settings unless indicated otherwise. This tool has been previously
used and validated in morphometric studies in schizophrenia
(Spalthoff et al., 2018), as well as in other neurologic and neurode-
generative diseases (Righart et al., 2017; Seiger et al., 2018). Processing
also included a two-step quality assurance: first, all images were vi-
sually inspected for artefacts (prior to pre-processing); secondly, all
underwent a statistical quality control for inter-subject homogeneity
and overall image quality as included in the CAT12 toolbox (“check
homogeneity” function) after segmentation. This second step again in-
cluded a visual inspection procedure for potential newly introduced
artefacts.
We used a volume-based tool (CAT12) which offers an alternative
that allows for faster processing (1 h per subject) and rapid learning by
the user while at the same time maintaining a high quality, when
compared to the well-established surface-based tool FreeSurfer.
FreeSurfer's steep learning curve for beginner users and high processing
time might demand considerable computational and time effort, parti-
cularly in larger studies. On the one hand, spherical and brain phan-
toms have confirmed that CAT accurately measures features of cortical
thickness and folding (Dahnke et al., 2013). On the other hand, CAT12
has been validated in clinical populations, and there is evidence that
CAT12 can be considered a fast and reliable alternative to FreeSurfer
(Righart et al., 2017; Seiger et al., 2018).
2.4. Gyrification analysis
We calculated local (vertex-wise) gyrification index (GI) maps based
on the absolute mean curvature approach (Luders et al., 2006). Ex-
traction of the cortical surface (using CAT12 routines) resulted in the
construction of a mesh of the central surface, i.e. the surface between
the grey matter/CSF border and the grey matter/ white matter
boundary (Dahnke et al., 2013). We then calculated the local absolute
mean curvature of this central surface by averaging the mean curvature
values from each vertex point within 3 mm from a given point. In a
second step, we applied 15 mm full-width at half maximum (FWHM)
smoothing to the GI maps. This method has been applied in previous
studies, also with other processing pipelines for cortical surface ex-
traction (Luders et al., 2012; Nenadic et al., 2015b)
2.5. Cortical thickness analysis
We analyzed cortical thickness based on the same algorithm for
extraction of the cortical surface implemented in CAT12, as given above
for GI analyses. Here, the central surface as well as cortical thickness
are estimated in one step using a projection-based distance measure
(Dahnke et al., 2013). The vertex-wise cortical thickness measures were
resampled and smoothed using a 15 mm FWHM Gaussian kernel.
2.6. Voxel-based morphometry (VBM)
We applied spatial normalization and segmentation into three voxel
classes: grey matter (GM), white matter (WM) and cerebrospinal fluid
(CSF) using partial volume segmentation with adaptive maximum a
posteriori (MAP) approach. We also determined total intracranial vo-
lume (TIV) for all scans. Using modulated normalized GM maps, we
tested the hypothesis of regional grey matter volume (GMV) differ-
ences. The extracted GM maps were smoothed using a 12 mm FWHM
kernel and used for further analysis. We applied a 0.1 absolute masking
threshold to the VBM data.
2.7. Statistical analysis
We performed statistical analyses of imaging data in the CAT12/
SPM12 statistical module applying ANOVA to each of the three mor-
phometric measures (gyrification and cortical thickness with SBM, and
GM volume with VBM). Using age and gender as covariates (and for
VBM analyses, additionally, total intracranial volume, TIV), we tested
group differences applying thresholds of p < 0.05 with FWE correction
for multiple comparisons. When the FWE was too stringent, and not to
miss an exploratory interesting effect, we thresholded the statistical
map at voxel level with p < 0.001 and then corrected at the cluster
level with non-stationary cluster extent correction. In addition, when
there was a significant group effect, we did post-hoc pairwise com-
parisons with t-test to detect differences between every pair of groups,
using Bonferroni correction for multiple comparisons.
Demographic and clinical data analysis was performed with IBM
SPSS Statistics 23 (IBM Corporation, New York, EUA). Normality of the
data was tested using the Shapiro–Wilk test. When data were normally
distributed, parametric ANOVA and t-tests were used to test differences
between groups, and Pearson correlation was used to calculate corre-
lation between imaging and clinical data. If the assumption of nor-
mality was not met, non-parametric Kruskal–Wallis H test and
Mann–Whitney U tests were used to assess between-group differences,
while Spearman correlation was used to assess the relationship between
morphometric measures and clinical scores.
Study design and data analysis were aligned with the Strengthening
the Reporting of Observational Studies in Epidemiology (STROBE)
consensus (Vandenbroucke et al., 2007).
3. Results
3.1. Descriptive analysis
Demographic and clinical data are summarized in Table 1. Re-
garding inpatient admissions of BPD participants, most (58%) were due
to manic episodes; all admissions of patients with SCZ involved psy-
chotic relapses. All patients with SCZ (n = 20) were on stable anti-
psychotic (AP) medication, predominantly atypical APs: one second-
generation AP (n = 16), a combination of two second-generation AP
(n = 2) or a first-generation AP (n = 2). In the BPD group (n = 20),
two patients were stable without any medication; most individuals
(n = 18) were on regular mood-stabilizing medication: mood-stabilizer
monotherapy (n = 7), mood-stabilizers in association (n = 1), a mood-
stabilizer and atypical AP combination (n = 4), and atypical AP, either
in monotherapy (n = 4) or combination (n = 2). Only one individual
was medicated with lithium.
Patient groups (SCZ and BPD) had no relevant demographic or
clinical differences besides antipsychotic exposure, greater in SCZ pa-
tients (p = 0.032). Regarding psychopathological evaluation, patients
with SCZ had greater (p < 0.001) general psychopathology scores, and
worse (p = 0.001) functioning than BPD patients. Individuals in the
BPD group had higher (p = 0.044) insight than SCZ patients. As ex-
pected, the SCZ group had much higher scores (p < 0.001) on the
Schizo-Bipolar Scale than BPD individuals: higher scores are associated
with prototypical SCZ syndromes, while paradigmatic BPD cases score
lower (Keshavan et al., 2011).
Groups were balanced for gender, exactly the same within-group
distribution (χ(2) = 0.000, p= 1.000), and age. The data on estimated
total intracranial volume (TIV) and total grey matter (GM) distribution
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were normally distributed for each group, as assessed by Shapiro–Wilk
tests (p > 0.05 for all tests). There was no statistically significant dif-
ference in mean age between groups as determined by one-way ANOVA
(F(2,57) = 0.008, p = 0.992). Adjusting the estimates of TIV and total
GM for age, there was also no significant difference in mean TIV be-
tween groups (F(2,57) = 0.710, p = 0.496) or total GM volume (F
(2,57) = 1.471, p = 0.238) between groups (Fig. 1).
3.2. Voxel-based morphometry
3.2.1. Grey matter volume
VBM analysis revealed a group effect on regional GM volume
(F = 23.99; p = 0.003, FWE corrected) in the right globus pallidus, at
MNI coordinates [18–2 5] (Fig. 2, top). Post-hoc analyses revealed
significantly increased (t = 6.62; p < 0.001, with Bonferroni correc-
tion) GM volume in the right globus pallidus of SCZ patients compared
to CNT (Fig. 2, bottom). We did not observe significant correlation
between the volume of globus pallidus and age, TIV, total GM volume,
disease duration or medication in any group (all p > 0.05).
3.3. Gyrification analysis
Gyrification analysis revealed a group effect on the gyrification
index in left supramarginal gyrus - BA40 (F= 10.17; p< 0.001) at MNI
coordinates [−44 −45 41] and right inferior frontal gyrus - BA47
(F = 8.41; p = 0.001) at MNI coordinates [32 40 −11]. Post-hoc
analyses revealed increased gyrification in patients with BPD compared
to SCZ in the left supramarginal gyrus - BA40 (t = 4.13; p < 0.001,
Bonferroni corrected), while local gyrification index (LGI) of healthy
controls was in between the clinical groups. SCZ patients had sig-
nificantly decreased gyrification compared to controls (t = 3.37;
p = 0.005, Bonferroni corrected). In what regards the right inferior
frontal gyrus – BA47, the SCZ group had lower gyrification compared to
healthy controls (t = 4.18; p < 0.001, Bonferroni corrected) and to
BPD (t = 2.52; p = 0.048, Bonferroni corrected), which in turn had
decreased gyrification compared to controls as well, although not sig-
nificantly. Results are shown in Fig. 3.
3.4. Correlational analysis between morphometric and psychopathological
measures
We explored the relation between psychopathological data and right
GP regional GM volume, namely in subgroups BPD, SCZ and controls. In
BPD patients there was a negative association between GP volume and
functioning – higher PSP score (Spearman rho = −0.503, p = 0.024),
and also with insight – higher ITAQ score (Spearman rho = −0.462,
p = 0.040). Similar correlations were found when analyzing both
clinical samples as a single group: a larger GP volume was associated
with worse functioning (Spearman rho = −0.359, p = 0.023) and
insight (Spearman rho = −0.420, p = 0.007); a positive association
Table 1
Demographic and clinical data of study groups.
N= Schizophrenia Bipolar disorder Healthy controls test statistics p-value
20 20 20
Gender distribution (female/male) 7/13 7/13 7/13 χ2 0.000 1.000
Age - years (SD) 31.5 (10.3) 31.65 (10.0) 31.5 (10.3) F 0.001 .992
Education - years (SD) 13.6 (3.7) 13.85 (2.64) 14.9 (4.52) F 0.756 .474
Total intracranial volume - ml (SD) 1469.31 (27.18) 1484.58 (37.73) 1523.80 (33.44) F 0.710 .496
Age of disease onset – years (SD) 25.6 (6.9) 26.5 (8.8) n/a t −0.276 .784
Duration of disease – years (SD) 6.0 (7.9) 5.2 (4.3) n/a t 0.297 .769
Inpatient admissions (min-max) 1.25 (0–7) 1.25 (0–4) n/a t 0.000 1.000
Antipsychotic exposure (CPZE) – mg (SD) 380.0 (337.3) 160.8 (272.3) n/a t 2.226 .032
History of psychotic symptoms 20/20 16/20 n/a χ2 0.035 ,106
History of substance abuse 5/20 7/20 n/a χ2 0.557 ,731
History of suicidal behaviors 4/20 4/20 n/a χ2 0.000 1000
Psychopathology - BPRS (SD) 35.65 (6.41) 29.11 (2.61) n/a t 3.991 .000
Functioning – PSP (SD) 80.22 (12.36) 92.00 (4.00) n/a t −3.845 .001
Insight – ITAQ (SD) 17.12 (3.16) 19.13 (2.22) n/a t −2.100 .044
Schizo-Bipolar Scale (min-max) 8.00 (7–9) 0.94 (0–2) n/a t 28.356 .000
BPRS = Brief Psychiatric Rating Scale; CPZE = chlorpromazine equivalents; ITAQ = Insight and Treatment Attitudes Questionnaire; PSP = Personal and Social
Performance Scale; SD = standard deviation;.
Fig. 1. Boxplots of the distribution of age (in years) and total intracranial volume (TIV, in ml) across participants in each group. No statistically significant differences
were observed between groups.
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with more severe general psychopathology – BPRS – was also found
(Pearson r = 0.314, p = 0.048) – results are shown in Fig. 4. Having
explored the relation of gyrification with clinical data, we found a
positive association between gyrification in the left BA40 and higher
antipsychotic dosage – chlorpromazine equivalents – in BPD patients as
a group (Spearman rho = 0.486, p = 0.030). Analyzing both SCZ and
BPD as a whole, higher gyrification in the left BA40 was associated with
lower scores in the Schizo-Bipolar Scale (Spearman rho = −0.535,
p < 0.001) and higher functioning (Spearman rho = 0.358,
p = 0.023); gyrification in the right BA47 correlated negatively with
CPZE – antipsychotics mean dosage (Spearman rho = −0.313,
p = 0.049). Results are presented in Fig. 4.
4. Discussion
The present work used a combined approach of conventional and
novel brain morphometric measures to compare individuals with ar-
chetypal SCZ or BPD syndromes in early years of disease. We found an
increased volume of the right globus pallidus in patients with SCZ, di-
vergent gyrification of the left supramarginal gyrus in BPD vs. SCZ, and
decreased gyrification of the right inferior frontal gyrus in SCZ.
Relevant associations between the imaging findings and psychopatho-
logical measures were also identified.
In line with previous studies, we observed an increase in the volume
of the globus pallidus (GP) in SCZ patients even at early stages of dis-
ease. The design of our study allowed a relatively reduced time of
exposure to possible confounding factors, such as disease duration and
antipsychotic treatment (van Erp et al., 2014). There is conflicting
evidence on the impact of disease duration on the volume of deep grey
matter, with some studies showing no effect (Fusar-Poli et al., 2013)
whilst others demonstrated a positive association with bilateral GP
volumes (Hashimoto et al., 2018). Although causality is uncertain, it
might be hypothesized that such morphological changes were acquired
rather than reflecting a neurodevelopmental nature.
Unlike atypical antipsychotics, classical antipsychotics have been
associated with generalized reductions in GM volume but with an en-
largement of the basal ganglia (Lang et al., 2004; Lieberman et al.,
2005). This has been corroborated by a recent meta-analysis reporting
that a daily dose of antipsychotics was positively associated with left GP
volume and negatively with right hippocampus volume (Hashimoto
et al., 2018). It was also associated positively with laterality index of
globus pallidus, while the class of antipsychotics did not seem to
modulate the effect on subcortical volume. Womer and colleagues also
found increased GP and caudate volumes in psychotic patients (both
SCZ and psychotic BPD), while non-psychotic BPD patients had the
smallest volumes, even when compared with healthy controls
(Womer et al., 2014). Findings of a larger globus pallidus and leftward
asymmetry in globus pallidus volume were also reported by the EN-
IGMA Schizophrenia working group (van Erp et al., 2014), and the
Japanese consortium (COCORO - Cognitive Genetic Collaborative Re-
search Organization), respectively (Okada et al., 2016).
In BPD patients, subcortical volumetric abnormalities have been
Fig. 2. Top: VBM analysis of group effects (schizophrenia – SCZ; bipolar disorder – BPD; healthy controls - CNT) on regional brain grey matter (GM). F-values of
clusters with significant differences (p < 0.05, FWE correction) are color coded and superimposed on template MNI space sections. Bottom: Boxplots of the
distribution of total GM volume (ml) and GM volume in the right globus pallidus (ml) across participants in each group. There is no statistically significant difference
between groups in total GM volume; *** indicates significant difference in the volume of globus pallidus in SCZ > CNT (post-hoc p < 0.001, Bonferroni corrected).
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assessed in the ENIGMA Consortium, demonstrating the presence of
enlarged lateral ventricles, and volume loss of the hippocampus and the
thalamus. For all other subcortical structures, including the globus
pallidus, no significant differences were identified vs. controls
(Hibar et al., 2016). In summary, as demonstrated in our study, rela-
tively well-controlled for confounding factors, the increased GP volume
documented in SCZ is not consistently found in BPD patients adjusted
for age and disease length.
Changes in gyrification found in our study should be interpreted in
light of the currently limited knowledge on this innovative biomarker,
in particular in populations with BPD. In SCZ, although more data are
available, conflicting findings have been reported as evidenced by the
presence of either hypo- or hyper-gyrification involving mostly pre-
frontal and temporal areas (Nanda et al., 2014; Spalthoff et al., 2018). It
has been hypothesized that gyrification rests on early developmental
disturbances, based on a smaller subset of brain areas showing devel-
opmental delay, while volumetric changes emerge only at later stages,
such as prodromes or clinical onset (Spalthoff et al., 2018; Zilles et al.,
2013).
Compared with healthy controls, we found increased gyrification of
the left supramarginal gyrus (SMG - BA40) in patients with BPD and a
decreased gyrification of the SMG in patients with SCZ. Given that BPD
and SCZ frequently share brain morphometric features (Ivleva et al.,
2010), these contrasting findings are relevant, but appear to corrobo-
rate the results of other morphologic and functional imaging studies
using classical volumetric and microstructural measures. In the EN-
PACT study (European Network on Psychosis, Affective disorders and
Cognitive Trajectory), the left SMG was one of the areas where grey
matter volume loss was most significant in clinical samples of BPD and
SCZ (Maggioni et al., 2017). In other studies it was observed a volume
reduction of the right SMG in SCZ (Amann et al., 2016) or in both SCZ
and, although at uncorrected level, BPD patients (Nenadic et al.,
2015b). Concerning structural connectivity, reduced and increased
fractional anisotropy were found in SCZ and BPD, respectively, with
increased mean GM diffusion in both clinical samples (Anderson et al.,
2013). A negative correlation was further identified between alex-
ythimia and reduced volume of the left SMG in SCZ patients
(Kubota et al., 2011). The SMG has been functionally associated with
social cognition and Theory of Mind, namely its more early developing
neural components (Saxe and Powell, 2006; Silani et al., 2013), and
social cognition deficits have been proposed as the most significant
predictors of functionality in patients with SCZ (Couture et al., 2006;
Fig. 3. Top: Surface-based morphometry analysis of group effects (schizophrenia – SCZ; bipolar disorder – BPD; healthy controls - CNT) on gyrification, corrected for
age and gender. Group differences (thresholded at voxel level with p < 0.001 and corrected with cluster level non-stationary cluster extent) are highlighted with
significance-levels visualized on a red to yellow scale and superimposed on a template reconstruction of brain surface in MNI space. An effect of group was found in
gyrification in left supramarginal gyrus (top left) and right inferior frontal gyrus (top middle and right). Bottom: Boxplots of the distribution of gyrification in left
supramarginal gyrus (BA40) and right inferior frontal gyrus (BA47) across participants in each group. Significant differences were found with the comparisons
BPD>SCZ (***p < 0.001) and CNT>SCZ (**p = 0.005) in left BA40; and BPD>SCZ (*p = 0.048) and CNT>SCZ (***p < 0.001) in right BA47.
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Madeira et al., 2016).
Our study showed decreased gyrification of the right inferior frontal
gyrus in schizophrenia, a finding that is corroborated by several func-
tional neuroimaging studies. In a fMRI study of BPD and SCZ patients
using a language-associated activation task, BPD patients engaged
emotion processing brain areas more than healthy controls and in-
dividuals with SCZ, recruiting the right BA47 to a greater extent
(McIntosh et al., 2008). Another fMRI study of euthymic BPD patients,
performing an affective task paradigm involving matching and labeling
of emotional facial expressions, reported reduced activation relative to
healthy controls in the right BA47 (Foland-Ross et al., 2012). Irre-
spective of structural thinning in BPD patients, it has been hypothesized
that the lateral section of the orbitofrontal cortex might suppress
amygdala output via a projection from the medial section (Foland-
Ross et al., 2011).
Our study represents an important contribution to the knowledge on
gyrification in patients with BPD and SCZ, and unlike previous studies
that focused on prefrontal gyrification our study assessed for the first
time whole-brain gyrification (McIntosh et al., 2009; Nenadic et al.,
2015). Nenadic and colleagues showed that BPD patients had increased
local gyrification in the right anterior infragenual cingulate cortex
compared to both SCZ and controls, and in left dorsolateral prefrontal
compared to controls, whereas the SCZ group exhibited increased
gyrification in the right anterior medial prefrontal cortex and orbito-
frontal cortex compared with controls (Nenadic et al., 2015a). We
found no gyrification differences of these regions in our sample, which
could be explained by imbalances in gender and age distribution in
their sample, as a larger proportion of male patients was found in the
SCZ subsample, and BPD patients had higher age compared to the SCZ
group (37.69 vs. 32.97 years). In our study, age and gender were well-
balanced across the 3 groups, and its sample was younger and had
shorter disease duration (5.2 and 6.0 years in BPD and SCZ) compared
to Nenadic's population (9.9 and 8.9 years, respectively), highlighting
earlier disease-specific changes, while minimizing the potential influ-
ence of late unspecific processes. Age could also have influenced
McIntosh and colleague's findings, given the higher mean-age of BPD
and SCZ patients (39.6 and 38.0 years, respectively), although gender
was balanced in both clinical groups and controls (McIntosh et al.,
2009). While reduced prefrontal gyrification was reported in BPD pa-
tients, these results were less evident than in SCZ individuals and the
parcellated gyrification index was calculated only in the ventral and
dorsal prefrontal sub-regions, limiting the anatomical characterization.
Also of note is that the clinical sample of that study was selected from
multiplex families, with every patient having at least one relative with
the same disorder, and thus limiting generalizability.
As described above, our study groups were gender-matched, which
is particularly relevant when considering the hypothesis formulated by
Timothy Crow that gender, interacting with laterality, might explain
some of the structural variance between BPD and SCZ patients; this is
supported by a recent meta-analysis (Bora et al., 2012; Crow et al.,
2013; Nenadic et al., 2015b). Hemispheric lateralization of mood reg-
ulation has also been reported, suggesting that positive or appetitive-
related emotions are lateralized towards the left, while negative or
aversive-related emotions are right-hemisphere biased (Foland-
Ross et al., 2011; Rotenberg, 2004). The relation of SCZ and BPD with
brain lateralization provided context to the asymmetric findings of
gyrification in our study. Differences regarding brain gyrification
findings could reflect regional variation in the abnormalities of gyr-
ification, with age, disease progression and neurodevelopmental fac-
tors, all influencing gyrification findings (Bo Cao et al., 2017;
Palaniyappan et al., 2011). Of interest to our findings of asymmetric
regional gyrification is a previous morphological study in SCZ
(Palaniyappan et al., 2011) showing that patients had significant hypo-
gyrification in most prefrontal regions. However the most striking
Fig. 4. Scatter plots of the distribution of compared imaging and clinical data across participants in each clinical group (schizophrenia – SCZ; bipolar disorder – BPD).
Top left: GP volume and functioning (Spearman rho = −0.359, p = 0.023); top center: GP volume and insight (Spearman rho = −0.420, p = 0.007); top-right:
gyrification in left BA40 and antipsychotic current dosage (Spearman rho = −0.313, p = 0.049); bottom-left: GP volume and general psychopathology (Pearson
r = 0.314, p = 0.048; the linear regression line is included only for this parametric relation); bottom-center: gyrification in left BA40 and Schizo-Bipolar scale score
(Spearman rho = −0.535, p < 0.001); bottow-right: gyrification in left BA40 and functioning (Spearman rho = 0.358, p = 0.023).
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finding was that the normal left>right pattern of prefrontal gyrification
was reversed in SCZ patients.
Long term challenges in differentiating schizophrenia from classic
manic-depressive psychosis, now considered as type I Bipolar Disorder
with psychotic features, suggest that common psychotic symptoms
could be a unifying feature for biomarker research (Ivleva et al., 2017;
Reininghaus et al., 2019). In fact, it has been hypothesized that gyr-
ification changes, namely in frontal regions, could be a phenotypic core
feature of psychotic disorders (Nenadic et al., 2015a). A study origi-
nated from the Bipolar-Schizophrenia Network on Intermediate Phe-
notypes (B-SNIP) consortium addressed gyrification in a sample of BPD,
SCZ, schizoaffective (SZA) patients, patient relatives and healthy con-
trols, using local gyrification index (Nanda et al., 2014). Significant
regionally localized hypogyria was reported in psychotic patients,
particularly in the cingulate cortex. Interestingly, direct BPD-SCZ
comparison yielded no significant results and SZA patients, a hypothetic
intermediate disorder to SCZ and BPD, appeared to exhibit a pro-
nounced profile of hypogyria. Study strengths, besides the availability
of unaffected patient relatives, included assessment of current medi-
cation, not only antipsychotic, but also lithium usage; lithium has been
shown to influence the structure of the human brain, namely increasing
GM volume (Lyoo et al., 2010; Moore et al., 2000). Of notice, only one
of our study's BPD patients was medicated with lithium. Nonetheless,
once again age and gender might have been limiting factors in the B-
SNIP consortium study, with higher mean-ages, and dramatic differ-
ences in the latter variable: 64% male patients in the SCZ group,
compared with 31% in the BPD sample, 47% of healthy controls and
29% of patient-relatives (Nanda et al., 2014)
Finally, when evaluating findings from different studies using a
novel parameter such as gyrification measures, methodological ques-
tions are obviously relevant. Although gyrification is thought to be a
stable marker, available open-source tools differ regarding labor in-
tensity and computational demands. We used a solid option that has
been validated in clinical settings – CAT12 – and is considered both fast
and reliable (Righart et al., 2017; Seiger et al., 2018). Furthermore,
gyrification values estimated with the commonly used FreeSurfer have
a higher rater-dependency than those estimated with the curvature
approach in CAT12, making this an easy-to-use alternative approach.
Despite our study's stringent design, namely inclusion/exclusion
criteria and matching for relevant variables such as age and gender,
some limitations should be discussed. The study's cross-sectional nature
hinders the investigation of specific disease trajectories, that only
longitudinal data might clarify (Cao et al., 2017). The relatively small
sample size, namely of particular subgroups such as non-psychotic BPD
patients (only 20% of the BPD group), precludes the assessment of some
variables, e.g. the influence of psychotic symptoms on BPD morpho-
metric changes. While we assessed and controlled for current medica-
tion use, namely antipsychotics, its possible effect as a confounder (e.g.
cumulative usage of antipsychotics) cannot be entirely ruled out.
5. Conclusions
A perceived feature of psychiatric neuroimaging research over the
past two decades has been its relative disconnection from real-world
clinical care and its unmet needs (Etkin, 2019). While MRI classification
studies using traditional GM measures have shown some promising
results in accurately separating individuals suffering from SCZ and BPD
(Schnack et al., 2014), brain imaging biomarkers would be more
clinically useful in earlier phases of disease, where these two disorders
can be hard to differentiate.
In this brain MRI comparison study of individuals with SCZ or BPD
in their first years of disease, we found an increased volume of the right
globus pallidus as a consistent marker in SCZ, but not BPD, when
evaluating traditional MRI measures. On the other hand, gyrification
was found to be differentially changed between clinical groups, diver-
ging from healthy controls in different directions in the left SMG gyrus,
and in the same direction, but with different strength, in the right in-
ferior frontal gyrus. The findings involving the left SMG gyrus are of
particular interest, given this contrasting pattern found in two disorders
that frequently share morphometric and genetic features (Ivleva et al.,
2010).
Gyrification analysis, an innovative and biologically plausible ap-
proach, could aid identification of biomarkers relevant to different as-
pects of pathophysiology in SCZ and BPD. Studies using these in-
novative morphometric features in early stage patients’ data could
enlighten specific disease trajectories, identifying distinct psycho-
pathological phenotypes and its core neurobiological processes, per-
haps generating helpful biomarkers for clinical practice, favoring ear-
lier diagnosis and improving treatment selection.
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